News and Updates

Dr. Zhen-Quan Xu Young Chinese Oncologist Training Fund

Dr. Zhen-Quan Xu Young Chinese Oncologist Training Fund is established by the children of the late Dr. Zhen-Quan Xu in 2017 in memory of their father, a highly respected Gastroenterologist and a Professor of Internal Medicine at the Shandong Medical University, Shandong, China.

首届中美国际肺癌学术会议:基础研究和临床应用

美中抗癌协会联合南京医科大学于2018年5月17日至19日在南京共同举办首届中美国际肺癌学术会议:基础研究和临床应用。会议将围绕肺癌基因组学、肺癌分子机制、肺癌液体活检、肺癌靶向治疗、肺癌免疫治疗等方面进行专题研讨。

美中抗癌协会会长美国杜克大学医学院终身教授Qingyi Wei与国家环境与人类健康国际联合研究中心沈洪兵主任为大会联合主席。美中抗癌协会董事会主席Wei Zhang和执行委员会成员Wei Zhou, Shi-Yong Sun, Jinsong Liu出席会议并做相关主题演讲.

CALL FOR APPLICATIONS: 2018 CSCO YOUNG INVESTIGATOR TRAVEL AWARDS

The AACR is pleased to announce a new partnership with the Chinese Society for Clinical Oncology (CSCO) offering 10 travel awards to AACR members attending the 2018 Annual Meeting to attend and present their work at the CSCO 21st Annual Meeting, to be held from September 19-23, 2018, in Xiamen China. The goal of the travel award is to promote international scientific exchange. The award includes complimentary registration, up to 4 nights’ accomodation, and up to US$1,000 towards the cost of travel expenses.

CJC: Our journal has an Impact Factor of 4.111 now, a big jump in History

We are pleased to announce that the 2016 Impact Factor (IF) of Chinese Journal of Cancer (CJC) is 4.111 according to the Journal Citation Reports released by the Clarivate Analytics on June 14, 2017.

A Big Jump

USCACA Participate in the Up-coming 20 CSCO Annual Meeting in Xiamen

USCACA will participate in the upcoming 20th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) (http://reg.csco.org.cn/reg2017en/) with a theme of "Together we innovate on our inheritance", to be held on Sept. 26-30, 2017 at Xiamen International Conference and Exhibition Center, Xiamen, Fujian, China. USCACA-CSCO will have a session entitled "Translating Science into Medicine – Early Phase Cancer Drug Development of Immuno-­‐oncology Combinations and Novel Targeted Agents” to be chaired by Helen Chen and Li Yan.

USCACA-CSCO Joint Session

Congratulations to the newly elected President Shi-Yuan Cheng at the ACACR Inaugural Meeting, April 2, 2017, Washington DC

Shiyuan Cheng, Professor at Feinberg School of Medicine of Northwestern University was elected as the new President of the newly formed Association for Chinese Americans in Cancer Research (ACACR) at the Inaugural Meeting, April 2, 2017 (also a joint meeting of USCACA and ACACR) at the 2017 AACR Annual meeting in Washington DC. Shi-Yuan was also the past President of USCACA (2013-2016), and his outstanding service for USCACA was recognized by an outstanding service plate presented by his successor, Qingyi Wei, the new President of USCACA.

USCACA Welcomes Its New President - Qingyi Wei

Qingyi Wei, Professor at Duke University School of Medicine was elected to be the new president of USCACA at the joint meeting of USCACA and ACACR at the 2017 AACR Annual meeting in Washington DC.

魏庆义,男,1983年获南京医科大学医学学士学位,1987年获中国预防医学科学院环境毒理学硕士学位,1992年5月获美国霍普金斯大学公共卫生学院博士学位。先后为美国M.D.Anderson癌症中心助理教授、副教授和终身教授以及冠名教授,杜克大学医学院医学系教授和美国NIH多个基金评审组成员、国际多个分子流行病学和医学杂志的主编(Cancer Medicine)、副主编 (International Journal of Molecular Epidemiology and Genetics)和编委,为20余种专业杂志的审稿人以及英国、德国、意大利、以色列、香港等国家和地区国家级科研基金评审人。


中国原创三代EGFR-TKI,期待中的下一个“明星”


在刚刚闭幕的IASLC WCLC 2016上,靶向药物无疑再次捍卫了其在晚期非小细胞肺癌(NSCLC)治疗领域的“明星”地位。新型靶点的探索,传统药物新治疗领域的拓展,液体检测在靶向药物疗效预测中的价值等研究,纷纷登录主席专场、口头报告、壁报等各种展示环节。

12月7日,在“靶向治疗新策略”口头报告环节发布的一项“突变选择性EGFR抑制剂AC0010(艾维替尼)在EGRF T790M非小细胞肺癌患者中的I、II期研究”,因其使用中国首个原创三代EGFR-TKI药物而备受关注。



Pages

Subscribe to RSS - News and Updates